Virax Biolabs Group (VRAX) FDA Approvals $2.20 -0.04 (-1.79%) Closing price 10/2/2026 03:54 PM EasternExtended Trading$2.14 -0.06 (-2.68%) As of 10/2/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsSEC Filings Virax Biolabs Group's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Virax Biolabs Group (VRAX). Over the past two years, Virax Biolabs Group has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ViraxImmune. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ViraxImmune FDA Regulatory Events ViraxImmune is a drug developed by Virax Biolabs Group for the following indication: Long COVID and Related Post-Acute Infection Syndromes. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Positive Data - May 26,2026Positive Data Drug: ViraxImmuneAnnounced Date: May 26, 2026Indication: Long COVID and Related Post-Acute Infection SyndromesAnnouncementVirax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS").AI SummaryVirax Biolabs Group Limited said early pilot data for ViraxImmune™, its blood-based test under development for Long COVID, ME/CFS, and related post-acute infection syndromes, showed positive signs. The company said the results are from the VRX003 study and are still very early, so they should be seen as preliminary. Virax said the findings will help guide ongoing test development and plans for future clinical validation. ViraxImmune™ is not approved for diagnostic use in any country. The company is working on T cell-based testing tools that may help measure immune responses and support a broader immunology profiling platform. Virax said these types of tests could have uses in conditions tied to immune system problems, including Long COVID and other chronic illnesses.Read Announcement Virax Biolabs Group FDA Events - Frequently Asked Questions Has Virax Biolabs Group received FDA approval? As of now, Virax Biolabs Group (VRAX) has not received any FDA approvals for its therapy in the last two years. What drugs has Virax Biolabs Group submitted to the FDA? In the past two years, Virax Biolabs Group (VRAX) has reported FDA regulatory activity for ViraxImmune. What is the most recent FDA event for Virax Biolabs Group? The most recent FDA-related event for Virax Biolabs Group occurred on May 26, 2026, involving ViraxImmune. The update was categorized as "Positive Data," with the company reporting: "Virax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS")." What conditions do Virax Biolabs Group's current drugs treat? Currently, Virax Biolabs Group has one therapy (ViraxImmune) targeting the following condition: Long COVID and Related Post-Acute Infection Syndromes. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Agenus FDA EventsInflaRx FDA EventsCentury Therapeutics FDA EventsObsidian Therapeutics FDA EventsSurrozen FDA EventsVera Therapeutics FDA EventsVerastem FDA EventsJohnson & Johnson FDA EventsTeva Pharmaceutical Industries FDA EventsAktis Oncology FDA EventsAgomAb Therapeutics FDA EventsArtiva Biotherapeutics FDA EventsArvinas FDA EventsBioCardia FDA EventsCandel Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Aethlon Medical FDA Events Bluejay Diagnostics FDA Events Adagio Medical FDA Events Beyond Air FDA Events Strata Skin Sciences FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:VRAX last updated on 5/26/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersLarry's Three-Step Strategy Revealed at The Dollar Trap SummitLarry unveiled a three-step strategy at last night's Dollar Trap Summit, with no options, futures, or cryptocu...Brownstone Research | SponsoredElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredA major gold reset could be closer than people thinkFor 50 years, Washington has held 8,133 tonnes of gold on its books at a fraction of today's market price. One...Reagan Gold Group | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virax Biolabs Group Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Virax Biolabs Group With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Positive Data - May 26,2026Positive Data Drug: ViraxImmuneAnnounced Date: May 26, 2026Indication: Long COVID and Related Post-Acute Infection SyndromesAnnouncementVirax Biolabs Group Limited today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS").AI SummaryVirax Biolabs Group Limited said early pilot data for ViraxImmune™, its blood-based test under development for Long COVID, ME/CFS, and related post-acute infection syndromes, showed positive signs. The company said the results are from the VRX003 study and are still very early, so they should be seen as preliminary. Virax said the findings will help guide ongoing test development and plans for future clinical validation. ViraxImmune™ is not approved for diagnostic use in any country. The company is working on T cell-based testing tools that may help measure immune responses and support a broader immunology profiling platform. Virax said these types of tests could have uses in conditions tied to immune system problems, including Long COVID and other chronic illnesses.Read Announcement
Free VRAX Stock Alerts